ANTIPAF Trial Nixes ARBs for Paroxysmal Atrial Fibrillation

EGMN -- Stand-alone angiotensin II receptor blocker therapy proved of no benefit in preventing recurrences of paroxysmal atrial fibrillation in patients without structural heart disease in a large German randomized double-blind trial.